CXCR2 Inhibition to Combat Pancreatic Ductal Adenocarcinoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 100卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：205 / 205
页数：1
相关论文
共 50 条
  • [1] CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
    Steele, Colin W.
    Karim, Saadia A.
    Leach, Joshua D. G.
    Bailey, Peter
    Upstill-Goddard, Rosanna
    Rishi, Loveena
    Foth, Mona
    Bryson, Sheila
    McDaid, Karen
    Wilson, Zena
    Eberlein, Catherine
    Candido, Juliana B.
    Clarke, Mairi
    Nixon, Colin
    Connelly, John
    Jamieson, Nigel
    Carter, C. Ross
    Balkwill, Frances
    Chang, David K.
    Evans, T. R. Jeffry
    Strathdee, Douglas
    Biankin, Andrew V.
    Nibbs, Robert J. B.
    Barry, Simon T.
    Sansom, Owen J.
    Morton, Jennifer P.
    CANCER CELL, 2016, 29 (06) : 832 - 845
  • [2] CXCR2 and its ligands modulate chemotherapy resistance in pancreatic ductal adenocarcinoma.
    Molczyk, Caitlin
    Prajapati, Dipakkumar R.
    Saxena, Sugandha
    Goel, Paran
    Varney, Michelle
    Singh, Rakesh K.
    CANCER RESEARCH, 2021, 81 (13)
  • [3] CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
    Awaji, Mohammad
    Saxena, Sugandha
    Wu, Lingyun
    Prajapati, Dipakkumar R.
    Purohit, Abhilasha
    Varney, Michelle L.
    Kumar, Sushil
    Rachagani, Satyanarayana
    Ly, Quan P.
    Jain, Maneesh
    Batra, Surinder K.
    Singh, Rakesh K.
    FASEB JOURNAL, 2020, 34 (07): : 9405 - 9418
  • [4] CXCR2 inhibition in pancreatic cancer: opportunities for immunotherapy?
    Morton, Jennifer P.
    Sansom, Owen J.
    IMMUNOTHERAPY, 2017, 9 (01) : 9 - 12
  • [5] Biotherapeutic strategies targeting the CXCR2 axis for depletion of myeloidderived suppressor cells in pancreatic ductal adenocarcinoma.
    Christopher, Ben N.
    Robinson, Reeder
    Reyes, Leticia
    Golick, Lena
    Basar, Ashton
    Dolloff, Nathan
    CANCER RESEARCH, 2022, 82 (22) : 134 - 135
  • [6] Blockade of CXC chemokines/CXCR2 axis in the tumor microenvironment as a potent therapeutic strategy for pancreatic ductal adenocarcinoma
    Ijichi, Hideaki
    Tada, Motohisa
    Miyabayashi, Koji
    Mohri, Dai
    Asaoka, Yoshinari
    Tateishi, Keisuke
    Ikenoue, Tsuneo
    Omata, Masao
    Koike, Kazuhiko
    Moses, Harold L.
    CANCER RESEARCH, 2011, 71
  • [7] CXCR2 inhibition suppresses acute and chronic pancreatic inflammation
    Steele, Colin W.
    Karim, Saadia A.
    Foth, Mona
    Rishi, Loveena
    Leach, Joshua D. G.
    Porter, Ross J.
    Nixon, Colin
    Evans, T. R. Jeffry
    Carter, C. Ross
    Nibbs, Robert J. B.
    Sansom, Owen J.
    Morton, Jennifer P.
    JOURNAL OF PATHOLOGY, 2015, 237 (01): : 85 - 97
  • [8] Biotherapeutic strategies targeting the CXCR2 axis for depletion of myeloid-derived suppressor cells in pancreatic ductal adenocarcinoma
    Christopher, Benjamin N.
    Reyes, Lety
    Robinson, Reeder
    Golick, Lena
    Dolloff, Nathan
    CANCER RESEARCH, 2024, 84 (02)
  • [9] Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
    Ijichi, Hideaki
    Chytil, Anna
    Gorska, Agnieszka E.
    Aakre, Mary E.
    Bierie, Brian
    Tada, Motohisa
    Mohri, Dai
    Miyabayashi, Koji
    Asaoka, Yoshinari
    Maeda, Shin
    Ikenoue, Tsuneo
    Tateishi, Keisuke
    Wright, Christopher V. E.
    Koike, Kazuhiko
    Omata, Masao
    Moses, Harold L.
    JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (10): : 4106 - 4117
  • [10] CXCR2 Inhibition Suppresses Metastasis and Improves the Response to Immunotherapy in Pancreatic Cancer
    Steele, Colin
    Karim, Saadia
    Leach, Josh
    Bailey, Peter
    Biankin, Andrew
    Nibbs, Rob
    Barry, Simon
    Sansom, Owen
    Morton, Jen
    CANCER RESEARCH, 2016, 76
12345